Podcast Summary: Plain English with Derek Thompson
Episode: Are GLP-1 Drugs "the Greatest Medical Breakthrough of the 21st Century"?
Release Date: January 31, 2025

Introduction: The Significance of GLP-1 Drugs

In this insightful episode of Plain English with Derek Thompson, host Derek Thompson delves into the transformative potential of GLP-1 receptor agonists (GLP-1 RAs) such as Ozempic and Mounjaro. Often hailed as revolutionary treatments for type 2 diabetes and obesity, these drugs are now being lauded by some scientists as "the greatest medical breakthrough of the 21st century." To unpack this enormity, Derek welcomes Dr. Ziad Al Ahli, a physician-scientist from Washington University in St. Louis and co-author of a groundbreaking study on GLP-1 drugs.

1. The GLP-1 Story: Serendipity and Significance [02:34 - 11:40]

Derek Thompson opens by drawing a parallel between the accidental discovery of penicillin by Alexander Fleming in 1928 and the serendipitous emergence of GLP-1 drugs. Just as penicillin became a cornerstone antibiotic, GLP-1 drugs were initially developed to treat type 2 diabetes but soon revealed unexpected benefits in weight loss and beyond.

Key Quote:
Derek Thompson: "[...] GLP-1 drugs was discovered essentially by mistake. In 1990 or in the early 1990s, a small team of scientists were studying the Gila Monster...**

2. Research Methodology: A Comprehensive Approach [11:41 - 17:35]

Dr. Ziad Al Ahli discusses the meticulous design of his study, which analyzed data from over two million veterans within the Veterans Affairs (VA) Medical System. By comparing individuals on GLP-1 drugs to multiple control groups—including those on other diabetes medications and a large "usual care" cohort—Al Ahli ensured a robust analysis of 175 health outcomes over a median follow-up of four years.

Notable Quote:
Ziad Al Ahli: "[...] we compared people who were, who started on GLP1 drugs versus several controls, looking comprehensively at all possible 175 health outcomes."

Key Points:

• Utilization of the VA database ensures equitable access to medications, eliminating socioeconomic biases.
• Comprehensive analysis covering a wide array of health outcomes to map the full impact of GLP-1 drugs.

3. Astonishing Benefits: Beyond Diabetes and Obesity [17:53 - 22:39]

The discussion shifts to the remarkable benefits uncovered in the study. GLP-1 drugs were associated with reduced risks across multiple health domains, including substance use disorders, schizophrenia, Alzheimer's disease, clotting disorders, and various infections.

Key Quotes:
Ziad Al Ahli:

• "[...] we saw a reduced risk of alcohol problems, cannabis use disorders, stimulant use disorders, opioid use disorders." [17:53]
• "[...] reduced risk of neurocognitive disorders, including Alzheimer's disease and dementia." [19:33]

Highlights:

• Substance Use Disorders: Significant reductions in alcohol, cannabis, stimulant, and opioid use disorders.
• Mental Health: Lowered risks of schizophrenia and other psychotic disorders.
• Neurocognitive Benefits: An 11% reduction in Alzheimer's and dementia risk.
• Cardiovascular and Infectious Diseases: Decreased incidence of clotting disorders and infections.

4. Understanding the Mechanisms: Brain and Body Interplay [22:39 - 35:17]

Al Ahli explores the potential biological mechanisms driving these extensive benefits. While the exact pathways remain partially understood, emerging research indicates that GLP-1 receptors in the brain influence affect, impulse control, and reward signaling. This neurological impact potentially explains the drugs' efficacy against a spectrum of disorders beyond metabolic regulation.

Notable Quote:
Ziad Al Ahli: "[...] people have GLP1 receptors in their brain. So that has been characterized in experiments now in areas of the brain that are sort of responsible for affect, for mood, for impulse control, and for reward signaling." [32:05]

Key Insights:

• Neurological Impact: GLP-1 drugs act on brain receptors affecting mood and impulses.
• Broad Biological Influence: Potential involvement in reducing neuroinflammation, oxidative stress, amyloid beta deposition, and tau protein hyperphosphorylation—all linked to Alzheimer's disease.

5. Risks and Side Effects: A Balanced Perspective [43:20 - 45:13]

While the benefits are substantial, Al Ahli emphasizes that GLP-1 drugs are not without risks. Common side effects include gastrointestinal issues like nausea and vomiting. The study also identified previously unreported risks such as hypotension (low blood pressure), sleep disturbances, headaches, and increased chances of kidney stones and pancreatitis.

Key Quote:
Ziad Al Ahli: "[...] GLP1 use was associated with reduced risk of seizures and neurocognitive disorders, the latter being driven by a decreased risk of dementia and Alzheimer's disease." [32:05]

Highlights:

• Known Risks: Nausea, vomiting, constipation, diarrhea, and gastroparesis.
• Newly Identified Risks: Low blood pressure, sleep problems, headaches, kidney stones, interstitial nephritis, and pancreatitis.

6. Discontinuation Rates: Cost vs. Side Effects [47:29 - 48:45]

A significant challenge with GLP-1 drugs is the high discontinuation rate, often between 30-40%. Al Ahli attributes the majority of discontinuations to affordability issues rather than side effects, although both factors are impactful.

Notable Quote:
Ziad Al Ahli: "Most people are discontinuing because they're not able to continue to afford it." [48:45]

Key Points:

• Affordability: High out-of-pocket costs are the primary reason for discontinuation outside the VA system.
• Side Effects: Approximately 30% discontinue due to adverse effects.
• Consequences of Discontinuation: Rapid weight regain and potential rebound in craving and related health risks.

7. Implications and Future Directions: Beyond GLP-1 [51:39 - 61:01]

The episode concludes with a forward-looking discussion on the broader implications of GLP-1 research. Al Ahli envisions a paradigm shift in understanding obesity as a chronic disease rather than a matter of willpower. He advocates for further research into other pleiotropic drugs—those with multiple, varied effects—and suggests that similar comprehensive studies could reveal untapped therapeutic potentials, much like what has been observed with statins and SGLT-2 inhibitors.

Key Quotes:
Ziad Al Ahli:

• "Obesity is a disease as a chronic disease that can be effectively treated with GLP1 drugs." [26:08]
• "[...] this drug is teaching us about the biology of Alzheimer's disease, about the biological pathways that are now implicated in this disorder or these diseases that we have not thought about previously." [54:42]

Highlights:

• Reconceptualizing Obesity: Recognizing obesity as a chronic, neurologically influenced disease.
• Pleiotropy in Medication: Encouraging exploration of other drugs with broad health impacts.
• Future Research: Utilizing advanced data analytics to uncover additional benefits and applications of existing medications.
• Public Health and Policy: Addressing affordability to ensure accessibility and sustained use of GLP-1 drugs.

Conclusion: A Transformative Potential Amid Challenges

Dr. Ziad Al Ahli and Derek Thompson underscore the transformative potential of GLP-1 drugs in addressing not only diabetes and obesity but a multitude of other health challenges. However, they also highlight the ongoing need to understand the full spectrum of benefits and risks, ensure affordability, and sustain patient adherence. As the story of GLP-1 continues to unfold, it holds promise for reshaping medical treatment paradigms and improving countless lives.

Notable Quotes Throughout the Episode:

• On Obesity as a Disease:
  Ziad Al Ahli: "Obesity is actually a disease as a chronic disease that can be effectively treated with GLP1 drugs." [26:08]

• On Pleiotropy and Drug Effects:
  Derek Thompson: "Let’s talk about the pleiotropic effects of other drugs like statins and how they might have broad beneficial profiles that we haven’t fully understood yet." [55:30]

• On Addiction and Consumption:
  Ziad Al Ahli: "GLP1 drugs are likely to ACT on the brain and they act to sort of not only curb appetite but also suppress other impulsive behaviors." [38:11]

• On Future Research Possibilities:
  Ziad Al Ahli: "Leveraging advanced causal inference methodologies can help us understand not only how to approach these diseases but also the underlying biology." [57:20]

Final Takeaway:

The advent of GLP-1 drugs marks a pivotal moment in medical science, offering hope for effectively managing obesity and potentially mitigating a range of other health issues. As research progresses, these drugs may redefine treatment strategies and enhance our understanding of complex biological systems, paving the way for future breakthroughs.